Advertisement

Cancer Drug Discovery and Development

Maximizing the Therapeutic Potential of Matrix Metalloproteinase Inhibitors for the Treatment of Cancer
  • Jeffrey S. Humphrey
  • Karen Price
  • Elora Gupta
  • Andrew Baxter
  • John Bird
  • Daryl Sonnichsen
  • Joseph Naglich
Chapter
Part of the Cancer Drug Discovery and Development book series (CDD&D)

Abstract

A significant amount of clinical research has been conducted with small molecules that inhibit matrix metalloproteinases (MMP), metal-containing enzymes that degrade the extracellular matrix and are implicated in tumor progression and angiogenesis (1–3). The majority of matrix metalloproteinase inhibitors (MMPIs) are designed with a concept similar to protease inhibitors used in the treatment of acquired immunodeficiency syndrome. MMPIs are currently under development for the treatment of a variety of diseases most notably cancer (3). Unlike conventional chemotherapy or radiation therapy, MMPIs are expected to slow tumor growth and prolong survival without causing detectable shrinkage of tumors. Because MMPIs are predicted to slow tumor growth but not shrink tumors, clinical development is not guided purely by objective tumor responses; proving the therapeutic value of these molecules will therefore require randomized placebo-controlled trials with assessment of the impact of drug treatment compared to placebo. Proof that these compounds are effective cytostatic agents will require demonstrating a survival advantage when compared to a placebo in a randomized, controlled trial.

Keywords

Clin Oncol Slow Tumor Growth Metastatic Pancreatic Cancer Matrix Metalloproteinase Inhibitor Blood Vessel Invasion 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Chambers AF, Matrisian LM. Changing views of the role of matrix metalloproteinases in metastasis. J Nati Cancer Inst 1997; 89: 1260–1270.CrossRefGoogle Scholar
  2. 2.
    Nelson AR, Fingleton B, Rothenberg ML, Matrisian LM. Matrix metalloproteinases: biologic activity and clinical implications. J Clin Oncol 2000; 18: 1135–1149.PubMedGoogle Scholar
  3. 3.
    McCawley LJ, Matrisian LM. Matrix metalloproteinases: multifunctional contributors to tumor progression. Molec Med Today 2000; 6: 149–156.CrossRefGoogle Scholar
  4. 4.
    Shi Z, Raithatha S, Spencer D, Rewcastle, B, Brasher P, Morris D, et al. Enhanced effectiveness of a novel MMP inhibitor, prinomastat (AG3340) with radiotherapy (RT) in a glioma model. Proc Am Assoc Cancer Res 2000; 41: 326 (2071a).Google Scholar
  5. 5.
    Herbst RS, Takeuchi H, Teicher BA. Paclitaxel/carboplatin administration along with antiangiogenic therapy in non-small-cell lung and breast carcinoma models. Cancer Chem Pharm 1998, 41: 497–504.CrossRefGoogle Scholar
  6. 6.
    Anderson IC, Shipp MA, Docherty A, Teicher BA. Combination therapy including a gelatinase inhibitor and cytotoxic agent reduces local invasion and metastasis of murine lewis lung carcinoma. Cancer Res 1996; 56: 715–718.Google Scholar
  7. 7.
    Shalinsky DR, Brekken J, Zou H, Bloom LA, McDermott CD, Zook S, et al. Marked antiangiogenic and antitumor efficacy of AG3340 in chemoresistant human non-small cell lung cancer tumors: single agent and combination chemotherapy studies. Clin Cancer Res 1999; 5: 1905–1917.PubMedGoogle Scholar
  8. 8.
    Teicher BA. A systems approach to cancer therapy. Cancer Metastasis Rev 1996; 15: 247–272.PubMedCrossRefGoogle Scholar
  9. 9.
    Kakeji Y, Teicher BA. Preclinical studies of the combination of angiogenic inhibitors with cytotoxic agents. Invest New Drugs 1997; 15: 39–48.PubMedCrossRefGoogle Scholar
  10. 10.
    Moore MJ, Hamm P, Eisenberg P, Dagenais M, Hagan K, Fields A, et al. A comparison between gemcitabine (GEM) and the matrix metalloproteinase (MMP) inhibitor BAY 12–9566 (9566) in patients (pts) with advanced pancreatic cancer. Proc Am Soc Clin Oncol 2000; 19: 240a (abstract).Google Scholar
  11. 11.
    Rosemurgy A, Buckels J, Charnley R. A randomized study comparing marimastat to gemcitabine as first line therapy in patients with non-resectable pancreatic cancer. Proc AmAssoc Cancer Res 1999; 18: 261a (abstract).Google Scholar
  12. 12.
    Fielding J, Scholefield J, Stuart R, Hawkins R, McCulloch P, Maughan T, et al. A randomized double-blind placebo-controlled study of marimastat in patients with inoperable gastric adenocarcinoma. Proc Am Soc Clin Oncol 2000; 19: 240a (abstract).Google Scholar
  13. 13.
    Ray JM, Stetler-Stevenson WG. Gelatinase A activity directly modulates melanoma call adhesion and spreading. EMBO J 1995; 14: 908–917.PubMedGoogle Scholar
  14. 14.
    Wojtowicz PS, Torri J, Johnson M, Steen V, Marshall J, Ness E, et al. Phase I trial of Marimastat, a novel matrix metalloproteinase inhibitor, administered orally to patients with advanced lung cancer. J Clin Oncol 1998; 16: 2150–2156.Google Scholar
  15. 15.
    Vu TH, Shipley JM, Bergers G, Berger JE, Helms JA, Hanahan D, et al. MMP-9/gelatinase B is a key regulator of growth plate angiogenesis and apoptosis of hypertrophic chondrocytes. Cell 1998; 93: 411–422.PubMedCrossRefGoogle Scholar
  16. 16.
    Gerber HP, Vu TH, Ryan AM, Kowalski J, Werb Z, Ferrara N. VEGF couples hypertrophic cartilage remodeling, ossification and angiogenesis during endochondral bone formation. Nat Med 1999; 5: 623–628.PubMedCrossRefGoogle Scholar
  17. 17.
    Ryan AM, Eppler DB, Hagler KE, Bruner RH, Thomford PJ, Hall RL, et al. Preclinical safety evaluation of rhuMAbVEGF, an antiangiogenic humanized monoclonal antibody. Toxicol Pathol 1999; 27: 78–86.PubMedCrossRefGoogle Scholar
  18. 18.
    Wedge SR, Ogilvie DJ, Dukes M, Kendrew J, Curwen JO, Hennequin LF, et al. ZD4190: an orally active inhibitor of vascular endothelial growth factor signaling with broad-spectrum antitumor efficacy. Cancer Res 2000; 60: 970–975.PubMedGoogle Scholar
  19. 19.
    Daniels R, Gupta E, Kollias G, Huang MQ, Patel RN, Manning J, et al. Safety and pharmacokinetics of BMS-275291, a novel matrix metalloproteinase inhibitor in health subjects. Proc Annu Meet Am Soc Clin Oncol 2001; (abstract) submitted.Google Scholar
  20. 20.
    Hurwitz H, Humphrey J, Williams K, Ness E, Conway A, Bielefield M, et al. A phase I trial of BMS275291: a novel, non-hydroxamate, sheddase-sparing matrix metalloproteinase inhibitor (MMPI) with no dose-limiting arthritis. Proc Annu Meet Am Soc Clin Oncol 2001; (abstract) submitted.Google Scholar
  21. 21.
    Lockhart AC, Braun RD, Dewhirst MW, Klitzman B, Humphrey JS, Yuan F, et al. Wound angiogenesis as a potential surrogate marker for anti-angiogenesis clinical trials. Proc Am Assoc Cancer Res 2000; 41: 168 (abstract).Google Scholar
  22. 22.
    Hurwitz H, Lockhart AC, Dewhirst MW, Klitzman B, Yuan F, Grichnik JM, et al. Evaluation of wound angiogenesis in healthy volunteers: a potential surrogate marker for antiangiogenesis agents. Proc Am Assoc Cancer Res 2000; 41: 168 (abstract).Google Scholar
  23. 23.
    Lockhart AC, Braun RD, Dewhirst MW, Humphrey J, Yuan F, Grichnik JM, et al. Wound angiogenesis inhibition as a marker for anti-angiogenic efficacy. Exp Biol 2000; (abstract).Google Scholar

Copyright information

© Springer Science+Business Media New York 2003

Authors and Affiliations

  • Jeffrey S. Humphrey
  • Karen Price
  • Elora Gupta
  • Andrew Baxter
  • John Bird
  • Daryl Sonnichsen
  • Joseph Naglich

There are no affiliations available

Personalised recommendations